A collaborative team of researchers has succeeded in revealing the high-resolution structures of amyloid β (Aβ40) fibrils ...

A collaborative team from Penn Medicine and Penn Engineering has uncovered the mathematical principles behind a ...

Note: Among the 20 tested antibodies, 1E4E11, 5H11C10, 2-48, Aβ-pE3, and Donanemab bs have known PTM-selectivity, which could not be fully addressed with the initial microarray consisting of ...

Note: Among the 20 tested antibodies, 1E4E11, 5H11C10, 2-48, Aβ-pE3, and Donanemab bs have known PTM-selectivity, which could not be fully addressed with the initial microarray consisting of ...

For monoclonal antibodies targeting Aβ clearance, we selected seven: Aducanumab, Bapineuzumab, Crenezumab, Donanemab, Gantenerumab, ... mAb with an IgG4 structure are more likely to cause ARIA-H than ...

PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind ...

This might be mediated by a vascular inflammatory response to amyloid angiopathy aggravated by anti-Aβ antibody. If this holds true, ... The ribbon structure of the γ-secretase complex is displayed ...

In this study, the research team has evaluated the use of a third type of microscopy, STED (stimulated emission depletion), to examine the structure and morphology of Aβ aggregates.

Acumen Pharmaceuticals is developing a monoclonal antibody, ACU193, that targets AβOs in Alzheimer's. Check out my recommendation on ABOS stock.

The distinct Aβ structure discovered in this study offers novel possibilities as the anti-GM1-Aβ antibodies are capable of recognizing and binding to this unique conformation.

The distinct Aβ structure discovered in this study offers novel possibilities as the anti-GM1-Aβ antibodies are capable of recognizing and binding to this unique conformation.